Growth Factors as Treatment Options for Intestinal Inflammation

Authors

  • BRIAN K. DIECKGRAEFE,

    1. Division of Gastroenterology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA
    Search for more papers by this author
  • JOSHUA R. KORZENIK,

    1. Inflammatory Bowel Disease Center, Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Search for more papers by this author
  • SHRIKANT ANANT

    1. Department of Medicine, Molecular Biology and Pharmacology, Siteman Cancer Center, Washington University School of Medicine, Saint Louis, Missouri, USA
    Search for more papers by this author

Address for correspondence: Brian K. Dieckgraefe, M.D., Ph.D., Gastroenterology, Campus Box 8124, 660 South Euclid Avenue, Washington University School of Medicine, St. Louis, MO 63110. Voice: 314-362-8940; fax: 314-362-8959.
 e-mail: dieck@im.wustl.edu

Abstract

Abstract: On the basis of several studies that have been completed to date, some growth factors appear promising for the treatment of inflammatory bowel disease: keratinocyte-like growth factor-2 (KGF-2), epidermal growth factor (EGF) enemas used in combination with oral mesalamine, somatropin (human growth hormone), and sargramostim (recombinant human GM–CSF). The results of these studies are highlighted and suggest that new insights into the regulation of intestinal immunity may provide effective synergistic or single-agent treatment alternatives to immunosuppression for inflammatory bowel disease. These data focus on the reparative components of mucosal homeostasis.

Ancillary